CIBC Private Wealth Group
SPRY icon

CIBC Private Wealth Group’s ARS Pharmaceuticals SPRY Stock Holding History

CIBC Private Wealth Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$247K – 3296
2025
Q1 		$247K Hold
20,000
– – ﹤0.01% 1011
2024
Q4 		$229K Hold
20,000
– – ﹤0.01% 1106
2024
Q3 		$290K Hold
20,000
– – ﹤0.01% 1033
2024
Q2 		$190K Hold
20,000
– – ﹤0.01% 1128
2024
Q1 		$189K Buy
+20,000
New +$149K ﹤0.01% 1142

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CIBC Private Wealth Group's SPRY Position: Q2 2025 in Review

CIBC Private Wealth Group sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 20,000 shares — an estimated $247K sold.

CIBC Private Wealth Group first reported a position in SPRY in Q1 2024 and held it in 5 quarters. The position peaked at $290K in Q3 2024. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

  • CIBC Private Wealth Group reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 20,000 ARS Pharmaceuticals shares in Q2 2025, an estimated $247K.
  • CIBC Private Wealth Group first reported a position in ARS Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • CIBC Private Wealth Group's ARS Pharmaceuticals position peaked at $290K in Q3 2024.
  • 187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on CIBC Private Wealth Group's 13F filing for Q2 2025, filed 12 Aug 2025.